Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been given an average rating of “Moderate Buy” by the twenty-seven analysts that are covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $96.1364.

Several equities analysts recently issued reports on EW shares. Wells Fargo & Company raised their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 12th. Piper Sandler reiterated an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th.

Insider Activity

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,371,239.08. The trade was a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 61,718 shares of company stock valued at $5,236,281. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after acquiring an additional 365,581 shares in the last quarter. State Street Corp raised its holdings in Edwards Lifesciences by 1.5% in the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares in the last quarter. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after purchasing an additional 989,533 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. Finally, Jennison Associates LLC lifted its position in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $81.82 on Tuesday. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The stock has a market cap of $47.52 billion, a PE ratio of 44.71, a PEG ratio of 2.13 and a beta of 0.93. The company’s fifty day moving average is $82.41 and its 200 day moving average is $81.58. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.